Age-related colorectal cancer risk correlates strongly with left-sided accumulation of mutated crypts r=0.598-0.643. I propose the butyrate gradient hypothesis: spatially defined microbial metabolite profiles epigenetically silence mismatch repair (MMR) genes in left-colonic crypt stem cells, establishing a mutation-permissive field before significant somatic mutations occur. This reframes MMR decline from a consequence to a localized, environmentally triggered initiator of field cancerization.

Mechanistic Rationale

The colon exhibits a pronounced microbiome gradient. Proximal (right) regions are fermentative, high in butyrate-producing Firmicutes; distal (left) regions have longer transit times, lower butyrate, and higher concentrations of secondary bile acids and genotoxic metabolites. Butyrate, at physiological concentrations in the right colon, acts as an HDAC inhibitor and generally promotes epithelial health. However, prolonged exposure or specific concentration thresholds in stem cell compartments could paradoxically drive pathological epigenetic reprogramming. Specifically:

1. Epigenetic Priming: Low, fluctuating butyrate in the left colon may fail to maintain active histone acetylation at MMR gene promoters (e.g., MLH1, MSH2), rendering them susceptible to de novo DNA methylation. This aligns with sporadic MLH1 hypermethylation being an early event found in 70% of aberrant crypt foci [PMC4791244].
2. Metabolic-Stress Synergy: The left colon's unique environment—higher oxidative stress from stagnation, secondary bile acids—could synergize with suboptimal butyrate signaling. Oxidative stress enhances the immunogenicity of MSH2/MSH6-silenced tumors, suggesting a pre-existing vulnerability. The gradient creates a "perfect storm": a local environment that both promotes MMR epigenetic silencing and selects for the survival/ expansion of crypts that acquire it.
3. Field Initiation: Widespread, low-penetrance epigenetic silencing of MMR in left-sided crypt stem cells would increase the basal somatic mutation rate across the field. Over decades, this leads to the observed high-density clusters of mutated crypts [PMC11159732]. The process starts with a metabolic/epigenetic lesion, not a genetic one.

This model resolves the temporal paradox: MMR silencing precedes and enables the mutation avalanche, driven by regional metabolic geography rather than stochastic events alone. It also potentially explains the rising incidence of early-onset CRC, where dysbiosis [PMC12966572] may abruptly establish a similarly pathological metabolite gradient in younger colons.

Experimental Validation

1. Spatial Mapping: Perform single-cell multi-omics (ATAC-seq, bisulfite sequencing, RNA-seq) on crypt stem cells from right vs. left human colon tissue. Predict: left-sided crypts show higher baseline MLH1 promoter methylation and repressive histone marks (H3K9me3, H3K27me3) even in histologically normal tissue.
2. Organoid Model: Expose human colon organoids derived from right-colon stem cells to a "left-colon" metabolite cocktail (low butyrate, high deoxycholate) vs. a "right-colon" cocktail (high butyrate). Measure MMR gene expression, mutation accumulation rates (via whole-genome sequencing over passages), and sensitivity to alkylating agents. Predict: left-like conditions induce MMR silencing and hypermutation.
3. Longitudinal Biomarker Study: In a cohort undergoing screening colonoscopies, measure fecal butyrate levels and analyze DNA methylation (via liquid biopsy) of MMR genes in shed colonocytes, tracking left vs. right sourcing. Correlate with future adenoma development. Predict: low fecal butyrate + high MLH1 methylation signal predicts left-sided neoplasia.

Falsification: If left-colon crypts do not exhibit distinct MMR epigenetic landscapes prior to mutation, or if organoids show no metabolite-dependent MMR silencing, the hypothesis is invalid. The model requires that the epigenetic defect is spatially regulated by the metabolome, not just random.